OSI-211 (Liposomal Lurtotecan)

liposomal lurtotecan · Astellas Pharma Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OSI-211 (Liposomal Lurtotecan), covering 2011-10-20 to 2011-10-20. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer [Phase 2]